REGENXBIO (NASDAQ:RGNX) exercised its option to license Clearside Biomedical’s (NASDAQ:CLSD) in-office, SCS Microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics.
The agreement includes, but is not limited to, RGX-314 delivery to the suprachoroidal space to potentially treat wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other conditions for which chronic anti-vascular endothelial growth factor treatment is currently the standard of care.
Under the accord, Clearside earned $2-million on REGENXBIO’s exercise of the option and signing of an original research agreement. Clearside also is eligible to receive up to $34-million in total development milestones across multiple indications, up to $102-million in sales milestones and mid-single digit royalties on net sales of products using the SCS Microinjector.
REGENXBIO will be responsible for all development, regulatory and commercialization activities for their gene therapy product candidates. Clearside will be responsible for supplying the SCS Microinjector in support of REGENXBIO’s clinical studies and commercial use.
“Our recent partnerships with REGENXBIO, Bausch Health, and Aura Biosciences demonstrate the broad applicability of our suprachoroidal space injection platform to potentially treat multiple ocular diseases,” George Lasezkay, CEO of Clearside, said in a statement.
Citing wet AMD and diabetic retinopathy as two of the most common causes of irreversible blindness in the U.S., Dr. Thomas Ciulla, CMO of Clearside, said utilizing the SCS Microinjector to deliver RGX-314 might provide patients with access to one-time gene therapy treatment in a range of patient care settings.
